Insilico Medicine Inc. has disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune and inflammatory disorders.

Shanghai Institute of Organic Chemistry has described leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory disorders, Parkinson’s disease and Alzheimer’s disease, among others.

Magicbullet Therapeutics Inc. has divulged protein kinase inhibitors reported to be useful for the treatment of cancer.

Lento Bio Inc. has synthesized cysteine derivatives reported to be useful for the treatment of presbyopia. An exemplified compound (Cpd in row 4 in tbl1 pg 20, claim 18) decreased in lens stiffness in C57BL/6 mice (at 20 mM; as eye drops).

Iregene Therapeutics (Suzhou) Co. Ltd. has identified pyrazolecarbonyl piperazinone compounds acting as bone morphogenetic protein receptor type-1B (BMPR1B) inhibitors reported to be useful for the treatment of cancer and pulmonary hypertension.

Circle Pharma Inc. has disclosed cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer.

Cellus Inc. has described cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.

Anticancer Bioscience Ltd. has identified compounds potentially useful for the treatment of cancer.

Sunshine Lake Pharma Co Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of multiple sclerosis, psoriasis, rheumatoid arthritis, atopic dermatitis, scleroderma, lupus nephritis, systemic lupus erythematosus and ulcerative colitis, among others.

Insilico Medicine Inc. has synthesized ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.